Clinical Trials Logo

Urinary Bladder, Overactive clinical trials

View clinical trials related to Urinary Bladder, Overactive.

Filter by:

NCT ID: NCT00409539 Completed - Clinical trials for Overactive Bladder Syndrome (OABS)

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with SMP-986 compared to placebo, as well comparing the change in: the severity of urgency episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr and the mean void volume/void between SMP-986 and placebo.

NCT ID: NCT00368706 Completed - Clinical trials for Urinary Bladder, Overactive

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

Start date: September 2006
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

NCT ID: NCT00366002 Completed - Clinical trials for Overactive Bladder (OAB)

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Start date: June 2006
Phase: Phase 4
Study type: Interventional

This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or tolterodine extended release (ER) therapy.

NCT ID: NCT00350636 Completed - Overactive Bladder Clinical Trials

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Start date: June 2006
Phase: Phase 3
Study type: Interventional

A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.

NCT ID: NCT00343486 Completed - Overactive Bladder Clinical Trials

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.

NCT ID: NCT00337558 Completed - Clinical trials for Urinary Incontinence

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)

SOLAR
Start date: May 2006
Phase: Phase 4
Study type: Interventional

This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes.

NCT ID: NCT00337090 Completed - Overactive Bladder Clinical Trials

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Start date: n/a
Phase: Phase 2
Study type: Interventional

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

NCT ID: NCT00321477 Completed - Overactive Bladder Clinical Trials

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.

NCT ID: NCT00311376 Completed - Overactive Bladder Clinical Trials

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.

NCT ID: NCT00293839 Completed - Clinical trials for Urinary Incontinence

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.